



FINAL – FOR IMMEDIATE RELEASE

Millendo Therapeutics to Present at Four Upcoming Conferences

ANN ARBOR, Mich., Feb. 2, 2016 – Millendo Therapeutics, Inc., a company developing novel therapies for rare and specialty endocrine diseases caused by hormone dysregulation, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at multiple conferences in February and early March. Details of the presentations are as follows:

Michigan Bio-Industry Growth Summit

Date: Wednesday, February 3, 2016

Time: 2:15pm EST

Location: Lansing, Michigan

BIO CEO & Investor Conference

Date: Monday, February 8, 2016

Time: 4:15pm EST

Location: New York City, New York

Leerink Partners Global Healthcare Conference

Date: Wednesday, February 10, 2016

Time: 8:00am EST

Location: New York City, New York

Cowen & Co. Health Care Conference

Date: Tuesday, March 8, 2016

Time: 10:30am EST

Location: Boston, Massachusetts

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options. Our clinical programs are designed to address:

- Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease in women
- Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the adrenal cortex
- Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of cortisol synthesis
- Endogenous Cushing's Syndrome (CS) – a condition resulting from chronic cortisol excess

Our experienced team is committed to bringing these first-in-class therapies to market.

www.millendo.com

###

Media Contact:

Blair McCarthy Atkinson

MacDougall Biomedical Communications

Main: +1 781 235 3060

Direct: +1 812 454 6257

batkinson@macbiocom.com